Cambridge Raman Imaging Limited (CRIL), a Frontier IP Group portfolio firm, has raised £250,000 to help commercialize its graphene-enabled scanning Raman microscope.
Cambridge Raman, a spin-out from the University of Cambridge, is jointly developing the technology with a spin-out from the Politecnico di Milano in Italy.
The investment will support the development of its graphene-based ultrafast laser technology for use in a medical microscope to diagnose and track tumors and other detection applications.
The microscope will generate real-time digital images of fresh tissue samples using Raman spectroscopy to differentiate between healthy and diseased tissue to show the extent of tumors, their response to drug treatments and to allow surgeons to see if cancer has been completely removed.
It is the first external equity investment in the company and values it at £1.5 million.